Comparative Pharmacology
Head-to-head clinical analysis: ADRUCIL versus METHOTREXATE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADRUCIL versus METHOTREXATE SODIUM.
ADRUCIL vs METHOTREXATE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorouracil (5-FU) is a pyrimidine analog that inhibits thymidylate synthase, interfering with DNA synthesis. It is metabolized to its active metabolites, which incorporate into RNA and DNA, causing cytotoxicity primarily in S-phase cells.
Methotrexate is a folate analog that inhibits dihydrofolate reductase (DHFR), blocking the conversion of dihydrofolate to tetrahydrofolate, thereby interfering with purine and pyrimidine synthesis, leading to inhibition of DNA replication and cell proliferation. It also has immunomodulatory effects via adenosine release.
12 mg/kg IV bolus daily for 4 days, then if no toxicity, 6 mg/kg IV on days 6, 8, 10, and 12; or 15 mg/kg IV weekly; or 500-600 mg/m2 IV every 3-4 weeks.
10-25 mg orally, intramuscularly, intravenously, or subcutaneously once weekly for rheumatoid arthritis; 7.5-15 mg orally once weekly for psoriasis. For oncology regimens, dosing varies (e.g., 50 mg/m² IV once weekly, or 1-5 g/m² IV with leucovorin rescue).
None Documented
None Documented
Biphasic elimination: initial t1/2α ~10-20 minutes, terminal t1/2β ~20-24 hours. Accumulation occurs with continuous infusion.
Terminal elimination half-life is 3-10 hours for low doses (≤50 mg/m²) and 8-15 hours for high doses (>50 mg/m²); in chronic therapy for rheumatoid arthritis, the half-life is approximately 5-8 hours.
Primarily hepatic metabolism; renal excretion of metabolites accounts for ~60-80% of the dose. Unchanged fluorouracil excreted renally is <10%. Fecal excretion is minimal (<5%).
Renal excretion accounts for 80-90% of elimination via glomerular filtration and active tubular secretion; biliary/fecal excretion accounts for 10-20%.
Category C
Category D/X
Antimetabolite
Antimetabolite